SEC Form SC 13G/A filed by NeuBase Therapeutics Inc. (Amendment)

1	Names of Reporting Persons.   DME Advisors LP
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a)            [ ]
	(b)            [ ]
3	SEC Use Only
4	Citizenship or Place of Organization.   Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5  Sole Voting Power   0 shares
		6  Shared Voting Power   18,040 shares
		7  Sole Dispositive Power   0 shares
		8  Shared Dispositive Power   18,040 shares
9	Aggregate Amount Beneficially Owned by Each Reporting Person   18,040 shares
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)     [ ]
11	Percent of Class Represented by Amount in Row (9)   0.5%
12	Type of Reporting Person (See Instructions)   IA

This Amendment No. 3 (the “Amendment”) to Schedule 13G relating to common stock, par value $0.0001 per share (“Common Stock”) of NeuBase Therapeutics, Inc., a Delaware corporation (the “Company” or the “Issuer”), is being filed with the Securities and Exchange Commission (the “SEC”) as an amendment to the Schedule 13G filed with the SEC on July 16, 2019, as amended on February 16, 2021 and February 14, 2022.  This Amendment is being filed on behalf of Greenlight Capital, Inc., a Delaware corporation (“Greenlight Inc.”), DME Capital Management, LP, a Delaware limited partnership (“DME CM”), DME Advisors, LP, a Delaware limited partnership (“DME Advisors”), DME Advisors GP, LLC, a Delaware limited liability company (“DME GP” and together with Greenlight Inc., DME CM and DME Advisors, “Greenlight”), and Mr. David Einhorn, the principal of Greenlight (collectively with Greenlight, the “Reporting Persons”).

This Amendment relates to Common Stock of the Issuer held by Greenlight for the account of private investment funds (the “Greenlight Accounts”) for which Greenlight acts as investment advisor or manages a portfolio (or serves as general partner of the investment advisor or manager of the portfolio) and with respect to which Mr. Einhorn may be deemed to have indirect investment and/or voting power as the principal of Greenlight and other affiliated entities.  DME GP is the general partner of DME CM.

The filing of this Amendment shall not be construed as an admission that any of the Reporting Persons is for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, the beneficial owner of any of the shares of Common Stock reported herein.  Pursuant to Rule 13d-4, each of the Reporting Persons disclaims all such beneficial ownership except to the extent of its pecuniary interest in any shares of Common Stock, if applicable.

This Amendment is being filed to amend and restate Items 4 and 5.

The information set forth in rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.  The percentages reported herein are calculated on the basis of a statement in the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 9, 2023, that there were 3,729,206 shares of Common Stock outstanding as of November 6, 2023.

Date:

February 14, 2024

* The Power of Attorney executed by David Einhorn, authorizing the signatory to sign and file this Schedule 13G on David Einhorn’s behalf, filed as Exhibit 99.1 to the Schedule 13D filed with the Securities and Exchange Commission on August 29, 2019 by the Reporting Persons with respect to the common units of CONSOL Coal Resources, is hereby incorporated by reference.